NCT05785325 is a Phase 2 clinical trial of RC48-ADC plus Bevacizumab in Colorectal Cancer, sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University.

Who is sponsoring NCT05785325?

NCT05785325 is sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University.

What drugs are being tested in NCT05785325?

Interventions in NCT05785325: RC48-ADC plus Bevacizumab.

What condition does NCT05785325 study?

NCT05785325 studies Colorectal Cancer.

Is NCT05785325 still recruiting?

NCT05785325 is currently status unknown. Last updated 31 October 2023.

Last reviewed 2023-10-31 · How we verify

NCT05785325

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

RC48-ADC Combined With Bevacizumab in HER2-positive Advanced Colorectal Cancer

Status unknown Phase 2 Last updated 31 October 2023

What this trial tests

Phase 2 trial testing RC48-ADC plus Bevacizumab in Colorectal Cancer in 30 participants. Status unknown.

Timeline

20 August 2023

Primary endpoint
1 December 2023

1 December 2024

Quick facts

Lead sponsor	Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	20 August 2023
Primary completion	1 December 2023
Estimated completion	1 December 2024
Sites	1 location across China

Drugs / interventions tested

RC48-ADC plus Bevacizumab — full drug profile →

Conditions studied

Colorectal Cancer — all drugs for Colorectal Cancer →

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Who can join

18 and older, any sex, with Colorectal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A phase II clinical study of RC48-ADC combined with Bevacizumab as late-line treatment in patients with HER2-expressed metastatic colorectal cancer. A total of 30 patients are planned to be enrolled.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

HER2-targeted therapies in cancer: a systematic review.
Zhu K, Yang X, Tai H, Zhong X, et al · · 2024 · cited 83× · PMID 38308374 · DOI 10.1186/s40364-024-00565-1
Current and emerging concepts for systemic treatment of metastatic colorectal cancer.
Steup C, Kennel KB, Neurath MF, Fichtner-Feigl S, et al · · 2025 · cited 10× · PMID 41047178 · DOI 10.1136/gutjnl-2025-335412
Molecular Landscape and Therapeutic Strategies against Colorectal Cancer.
Patel A, Gulhati P. · · 2024 · cited 7× · PMID 38672633 · DOI 10.3390/cancers16081551
HER2-targeted therapy in colorectal cancer: a comprehensive review.
Benli Y, Arıkan H, Akbulut-Çalışkan Ö. · · 2025 · cited 4× · PMID 40087250 · DOI 10.1007/s12094-025-03887-0
Targeting HER2 in Metastatic Colorectal Cancer: Current Therapies, Biomarker Refinement, and Emerging Strategies.
Vaghi C, Tosi F, Mauri G, Bonazzina E, et al · · 2026 · cited 2× · PMID 41247589 · DOI 10.1007/s40265-025-02253-2
Antibody-drug conjugates in colorectal cancer: advances in targeted delivery and personalized oncology.
Wang H, Yan X, Xia C, Chen D, et al · · 2026 · PMID 41768137 · DOI 10.3389/fbioe.2026.1756741

Verify or expand the search:

Other recruiting trials for Colorectal Cancer

Currently open trials in the same condition.

NCT07152821 — Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcino · Phase 3 · recruiting
NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
NCT07523919 — Functional and Respiratory Determinants of Long-Term Colorectal Cancer Outcomes · recruiting
NCT07529301 — Functional and Respiratory Predictors of Early Postoperative Outcomes · recruiting

Other Second Affiliated Hospital, School of Medicine, Zhejiang University trials

Trials by the same sponsor.

NCT07445152 — Research on Construction and Verification of Multimodal Medical Imaging Large Model · not yet recruiting
NCT06775665 — A Real-World Study on Hypertrophic Cardiomyopathy in Chinese Population · not yet recruiting
NCT07533422 — Rescue Reatment of Helicobacter Pylori Based on Fecal Antimicrobial Resistance Gene Testing · NA · not yet recruiting
NCT07487285 — A Non-inferiority Study of Laser Combined With Ultrasonic Debridement Therapy (LCUDT) Versus Manual Combined With Ultras · NA · not yet recruiting
NCT07505186 — Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05785325 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Second Affiliated Hospital, School of Medicine, Zhejiang University
Last refreshed: 31 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05785325.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing